Previous Close | 9.08 |
Open | 9.12 |
Bid | 9.24 x 1200 |
Ask | 9.28 x 800 |
Day's Range | 8.80 - 9.39 |
52 Week Range | 4.45 - 16.60 |
Volume | 189,294 |
Avg. Volume | 888,729 |
Market Cap | 532.559M |
Beta (5Y Monthly) | 1.79 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.10 |
Earnings Date | Mar 18, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 18.63 |
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Alan List, M.D. has been appointed as the Company’s Chief Medical Officer and a member of the senior leadership team at Precision BioSciences. Dr. List is a world-renowned hematologist with extensive academic and clinical experience in the research and development of hematology and oncology products. He has led clinical development programs for multiple FDA-approved drugs to treat hematologic malignancies, including myelodysplastic syndromes, acute leukemia, multiple myeloma, and lymphoma.
Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it has entered into a Program Purchase Agreement to reacquire all global development and commercialization rights for all CAR T partnered programs covered under its Development and Commercial License Agreement with Servier. This includes its two clinical stage CD19-targeting allogeneic CAR T candidates, PBCAR0191 and PBCAR19B stealth cell, as well as four additional product targets.
Stanley R. Frankel, M.D. has been appointed to the Board of Directors for Precision BioSciences.